



PSORIASIS

MYELODYSPLASTIC SYNDROME IN PSORIASIS

Dr Manjusha Rajendra Kuruwa⁽¹⁾

Sparsh Derma Centre, Heera Monghi Navneet Hospital, Mumbai, India⁽¹⁾

Title: Myelodysplastic Syndrome in a case of psoriasis induced by low dose methotrexate alone or with addition of cyclosporine, to highlight the key features and bring forth the overview.

Aim: Though pancytopenia or thrombocytopenia are known side effects of methotrexate, mostly in low doses are reversible. In our case, patient suffered from progressive myelodysplasia while on treatment for psoriasis and succumbed to death. A complete and exhaustive work up was done, and patient was assessed regularly for psoriasis and later with MDS.

History and clinical details: FEB 2015: A long standing case of psoriasis (13years) who received UVB and methotrexate off and on suddenly developed thrombocytopenia (37000) after she received it for arthralgia. The patient remained asymptomatic for 2 months even after methotrexate was stopped but developed wide spread lesions with extreme pruritus in APRIL 2015. After the haematological opinion deflazocort and cyclosporine were started. Patient developed severe pancytopenia & cellulitis, was hospitalised and labelled to have Myelodysplastic syndrome. She was administered chemotherapy (Azacytobin Dacitabin), repeated RBC transfusions and cyclosporine.

Conclusion: We have tried to review Myelodysplastic syndrome in detail with respect to immunosuppressants used in different dermatological conditions.

